Target intelligence / Profile preview

WW domain-binding protein 2 (WBP2)

Target
WBP2
Molecular classification
Other (transcriptional coactivator; not a classical enzyme, receptor, transporter, or ion channel)
01

Overview

WW domain-binding protein 2 is a transcriptional coactivator that binds to WW domain-containing proteins through its C-terminal PY motifs, particularly interacting with molecules like YAP, TAZ, estrogen, and progesterone receptors. It has a crucial role in oncogenic signaling, especially in breast cancer, by promoting the transcriptional activity of hormone receptors and Hippo pathway effectors. It is also essential for hearing, as mutations or loss of WBP2 result in progressive sensorineural hearing loss. WBP2's dual involvement in cancer progression and normal sensory signaling highlights its importance as a potential therapeutic target and biomarker for oncology and audiology applications[1][3][7][9].

Other names
WBP-2GRAMD6DFNB107WW domain binding protein 2WBP2WW domain-binding protein 2
02

Mechanism of action

Acts as a transcriptional coactivator enhancing the transactivation of estrogen and progesterone receptors by interacting via PY motifs with WW domain-containing proteins such as YAP and TAZ. Dysregulation can drive oncogenic signaling in breast and other cancers[1][3][7].

03

Biological functions

Transcriptional coactivationSignal transductionRegulation of hormone receptor signaling (estrogen receptor, progesterone receptor)Cell proliferationMaintenance of auditory function
04

Disease associations

Cancer (notably breast cancer)Hearing impairment (sensorineural hearing loss)Possibly other hormone-related and proliferative diseases
05

Safety considerations

Potential for off-target effects in normal tissues since WBP2 is involved in auditory function and basic cell signaling[3][7]Risks of disrupting hormone signaling pathways that may have systemic endocrine effects
06

Interacting drugs

None directly reported in the current literature as of 2024; research focuses on inhibition or modulation in cancer models, but no approved drugs specifically target WBP2[1][7][9]
07

Biomarkers

WBP2 protein or mRNA expression in tumors, especially breast cancer, as a biomarker for diagnosis, prognosis, and possibly response to hormone-targeted therapies[7]

Beyond the preview

Go deeper on WW domain-binding protein 2 (WBP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WW domain-binding protein 2 (WBP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call